Quarterly ResultApr 30, 2026, 04:25 PM
CORT Q1 Revenue $164.9M; Lifyorli FDA Approved; 2026 Guidance Raised
AI Summary
Corcept Therapeutics reported Q1 2026 revenue of $164.9 million, up from $157.2 million in Q1 2025. The company posted a net loss of $31.8 million, compared to a net income of $20.5 million in the prior year, primarily due to increased spending for the Lifyorli launch. Corcept announced FDA approval for Lifyorli (relacorilant) for platinum-resistant ovarian cancer in March 2026 and subsequently raised its 2026 revenue guidance to $950 – $1,050 million, expecting to return to profitability in Q2 2026.
Key Highlights
- Lifyorli (relacorilant) approved by FDA in March 2026 for platinum-resistant ovarian cancer.
- Increased 2026 revenue guidance to $950 – $1,050 million.
- Q1 2026 revenue was $164.9 million, up from $157.2 million in Q1 2025.
- Q1 2026 net loss was $31.8 million, compared to net income of $20.5 million in Q1 2025.
- Cash and investments stood at $515.4 million at March 31, 2026.
- Operating expenses increased to $214.5 million from $153.8 million YoY due to Lifyorli launch.
- Lifyorli plus nab-paclitaxel added to NCCN Guidelines® as a preferred regimen in April 2026.
- European Medicines Agency approval for relacorilant plus nab-paclitaxel expected by year-end.